140 related articles for article (PubMed ID: 28004636)
1. LIGHTing tumor up for checkpoint blockade.
Liang Y; Peng H
Oncotarget; 2016 Aug; 7(31):48857-48858. PubMed ID: 28004636
[No Abstract] [Full Text] [Related]
2. LIGHT May Improve Immune Checkpoint Blockade Response.
Cancer Discov; 2016 Jun; 6(6):OF9. PubMed ID: 27080334
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
4. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
[TBL] [Abstract][Full Text] [Related]
5. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma.
Genovese G; Venegoni L; Fanoni D; Tourlaki A; Brambilla L; Berti E
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):e269-e271. PubMed ID: 30835883
[No Abstract] [Full Text] [Related]
8. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
9. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
10. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
Callea M; Pedica F; Doglioni C
Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
[TBL] [Abstract][Full Text] [Related]
11. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
12. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Yang HY; Sun LJ; Mao YL
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
[No Abstract] [Full Text] [Related]
13. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Gibney GT; Weiner LM; Atkins MB
Lancet Oncol; 2016 Dec; 17(12):e542-e551. PubMed ID: 27924752
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.
Rangan L; Galaine J; Boidot R; Hamieh M; Dosset M; Francoual J; Beziaud L; Pallandre JR; Lauret Marie Joseph E; Asgarova A; Borg C; Al Saati T; Godet Y; Latouche JB; Valmary-Degano S; Adotévi O
Oncotarget; 2017 Jul; 8(30):48959-48971. PubMed ID: 28430664
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for assessing the effectiveness of immunotherapy in breast cancer.
Nixon MJ; Balko JM
Biomark Med; 2018 Feb; 12(2):97-100. PubMed ID: 29338306
[No Abstract] [Full Text] [Related]
17. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
19. PD-1 and its ligands are important immune checkpoints in cancer.
Dong Y; Sun Q; Zhang X
Oncotarget; 2017 Jan; 8(2):2171-2186. PubMed ID: 27974689
[TBL] [Abstract][Full Text] [Related]
20. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
[Next] [New Search]